Narayanan Santhosh
Department of Medicine, Government Medical College, Kozhikode, Kerala, India.
J Blood Med. 2017 Feb 23;8:21-27. doi: 10.2147/JBM.S129111. eCollection 2017.
Myelodysplastic syndrome (MDS), a disorder of clonal hematopoiesis, is an important clinical entity, but most of the studies available are conducted among the Western population. Its etiological factors and clinicohematological profile in the Indian population are quite diverse. The information regarding its prognostic factors and cytogenetics is very scarce.
(1) To assess the clinicohematological profile, cytogenetics, prognostic factors, and outcome of MDS and (2) to study its progression to acute myeloid leukemia (AML) in the selected patients over the study period.
A prospective observational study was performed with patients from Department of Medicine and Hematology, Government Medical College, Kozhikode, who were diagnosed with MDS within the study period (from 1 January 2014 to 31 July 2015). Secondary causes of dysplasia were excluded. In possible cases, the international prognostic scoring system was followed. These patients were followed up for an additional 6 months to assess the progression of MDS to AML based on symptoms, signs, hemogram, or repeat peripheral smear/bone marrow studies.
Of the 60 patients, 73% were aged >60 years. Disease was common in males, with a male:female ratio of 7:3. Thirty-five percent of the patients were working in agricultural and allied fields and had pesticide exposure. Patients with prior radiation exposure had significant association with adverse outcome. Fatigue was the prominent symptom and was reported by 90% of the patients. Blasts were >5% in peripheral smear; bone marrow cytopenia and dysplasia at the time of diagnosis had significant association with risk of transforming to AML. Refractory anemia (RA), observed in 22 patients, was the most common type of MDS. Most of the patients with RA with excess blasts type-1 and RA with excess blasts type-2 transformed to AML, and the association was statistically significant. Deletion of short arm of fifth chromosome (5q deletion) was detected in 11 patients. All of them showed good response to treatment with lenalidomide and had a favorable outcome.
This study highlights the various etiological factors, and the clinical profile of MDS seen in the Indian population. Cytogenetic analysis and application of the international prognostic scoring system has a significant bearing on the outcome, as exemplified by the response to lenalidomide in patients with 5q deletion. This study also indicates that proper diagnostic and prognostic assessment is necessary to institute appropriate therapeutic options.
骨髓增生异常综合征(MDS)是一种克隆性造血疾病,是一个重要的临床实体,但现有的大多数研究是在西方人群中进行的。其在印度人群中的病因及临床血液学特征差异很大。关于其预后因素和细胞遗传学的信息非常匮乏。
(1)评估MDS的临床血液学特征、细胞遗传学、预后因素及转归;(2)研究在研究期间选定患者中MDS进展为急性髓系白血病(AML)的情况。
对来自科泽科德政府医学院内科和血液科的患者进行了一项前瞻性观察研究,这些患者在研究期间(2014年1月1日至2015年7月31日)被诊断为MDS。排除发育异常的继发原因。在可能的情况下,遵循国际预后评分系统。对这些患者进行了额外6个月的随访,以根据症状、体征、血常规或重复外周血涂片/骨髓检查评估MDS进展为AML的情况。
60例患者中,73%年龄>60岁。疾病在男性中更为常见,男女比例为7:3。35%的患者从事农业及相关领域工作且接触过农药。既往有辐射暴露的患者与不良预后有显著关联。疲劳是最突出的症状,90%的患者有此症状。外周血涂片原始细胞>5%;诊断时骨髓血细胞减少和发育异常与转化为AML的风险有显著关联。22例患者中观察到难治性贫血(RA),是MDS最常见的类型。大多数1型伴过多原始细胞的RA和2型伴过多原始细胞的RA患者转化为AML,且这种关联具有统计学意义。11例患者检测到5号染色体短臂缺失(5q缺失)。他们均对来那度胺治疗表现出良好反应且预后良好。
本研究突出了印度人群中MDS的各种病因及临床特征。细胞遗传学分析和国际预后评分系统的应用对预后有重大影响,5q缺失患者对来那度胺的反应即为例证。本研究还表明,进行适当的诊断和预后评估对于制定合适的治疗方案是必要的。